Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostication model based on genomic expression in the tumor microenvironment of ER positive, HER2-negative stage III breast cancer via machine learning.
Authors
Yara Abdou
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Yara Abdou, Jessica Jerez, Andrew Baird, Jillian Dolan, Seongwon Lee, Shinyoung Park, Sunyoung S. Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 3)
Abstract #
3
Poster Bd #
A2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
First Author: Elisa Agostinetto
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2012 ASCO Annual Meeting
Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment.
First Author: William Fraser Symmans
Poster
2024 ASCO Annual Meeting
Predicting epirubicin response in Danish patients with breast cancer.
First Author: Ida Kappel Buhl